AbCellera Biologics Inc. (ABCL) — Available-Data Snapshot

We don't publish a discounted-cash-flow fair value for AbCellera Biologics Inc. (ABCL) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, ABCL trades at a recent price of $12.50, a market capitalisation of about $4,050,592,000, sitting 80% of the way up its 52-week range ($2.75–$15.02), on the NasdaqGS.

The standard alternative to a DCF is relative valuation — comparing ABCL's trading multiples against a sector benchmark. Here that gives P/B of 4.3× (cheaper than the peer median of 8.3×); P/S of 61.2× (richer than the peer median of 6.8×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. ABCL shows a price-to-book (P/B) of 4.27 and book value of $2.92 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. ABCL is in an up-trend (price above both its 50- and 200-day averages), trading -16.7% from its 52-week high. Over the past year the stock is +194.8%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.